A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
暂无分享,去创建一个
G. Lahat | Y. Greenman | N. Stern | O. Shibolet | D. Shor | J. Klausner | I. Wolf | R. Geva | A. Blachar | I. Bar-Yishay | Y. Sofer | E. Osher | N. Lubezky | Sharon Pelles | E. Scapa | S. Shamai | Y. Goykhman | A. Aizic | Eiman Shalabna | Oz Yakir
[1] M. Picchio,et al. A Single-center Prospective Observational Study Investigating the Accuracy of Preoperative Diagnostic Procedures in the Assessment of Lymph Node Metastases in Nonfunctioning Pancreatic Neuroendocrine Tumors , 2022, Annals of surgery.
[2] M. Falconi,et al. RELIABILITY OF PREOPERATIVE PANCREATIC NEUROENDOCRINE TUMORS GRADING ON ENDOSCOPIC ULTRASOUND SPECIMENS: A SYSTEMATIC REVIEW WITH META-ANALYSIS OF AGGREGATE AND INDIVIDUAL DATA. , 2022, Gastrointestinal endoscopy.
[3] Yijun Wang,et al. Prognostic Nomogram Based on the Metastatic Lymph Node Ratio for T1-4N0-1M0 Pancreatic Neuroendocrine Tumors After Surgery , 2022, Frontiers in Oncology.
[4] Wenquan Wang,et al. Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike? , 2021, Critical reviews in oncology/hematology.
[5] C. Bassi,et al. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases , 2021, Neuroendocrinology.
[6] F. Giovinazzo,et al. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs) , 2020, Frontiers in Endocrinology.
[7] K. Lillemoe,et al. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma , 2020, Annals of surgery.
[8] R. Bundschuh,et al. Therapy of Patients with Neuroendocrine Neoplasia—Evidence-Based Approaches and New Horizons , 2019, Journal of clinical medicine.
[9] elliot k fishman,et al. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[11] C. Schade-Brittinger,et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival , 2016, Neuroendocrinology.
[12] R. Jensen,et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.
[13] Xiaxing Deng,et al. Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors , 2015, Chinese medical journal.
[14] P. Ruszniewski,et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.
[15] K. Trinkaus,et al. Regional Lymphadenectomy Is Indicated in the Surgical Treatment of Pancreatic Neuroendocrine Tumors (PNETs) , 2014, Annals of surgery.
[16] P. Balladur,et al. Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinoma. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] A. Scarpa,et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. , 2012, European journal of cancer.
[18] A. Benson,et al. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. , 2011, International journal of radiation oncology, biology, physics.
[19] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[20] H. Ohge,et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. , 2010, Journal of the American College of Surgeons.
[21] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Scarpa,et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] C. Ko,et al. Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients , 2008, Annals of surgery.
[24] H. Reber,et al. Resection of pancreatic neuroendocrine tumors: results of 70 cases. , 2006, Archives of surgery.
[25] D. Santini,et al. Endocrine pancreatic tumors: factors correlated with survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] E. Kebebew,et al. A Lymph Node Ratio–Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors , 2018, The Journal of clinical endocrinology and metabolism.
[27] B. Pockaj,et al. Importance of Lymph Node Involvement in Pancreatic Neuroendocrine Tumors: Impact on Survival and Implications for Surgical Resection , 2014, Journal of Gastrointestinal Surgery.
[28] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.